转移性尿路上皮癌-话题@MedSci

#转移性尿路上皮癌#

35篇内容 | 2121人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1395036, encodeId=c1381395036bb, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Lancet oncol：卡博替尼治疗铂耐药的转移性尿路上皮癌, objectType=article, longId=197427, objectId=6caa19e42798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6caa19e42798, replyNumber=0, likeNumber=100, createdTime=2020-07-14, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6caa19e42798, moduleTitle=Lancet oncol：卡博替尼治疗铂耐药的转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6caa19e42798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395035, encodeId=41981395035d2, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, objectType=article, longId=196892, objectId=c2de19689221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2de19689221, replyNumber=0, likeNumber=58, createdTime=2020-07-03, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2de19689221, moduleTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2de19689221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395034, encodeId=14fb139503478, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, objectType=article, longId=196293, objectId=15011962937c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15011962937c, replyNumber=0, likeNumber=75, createdTime=2020-06-24, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15011962937c, moduleTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15011962937c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395033, encodeId=c7b713950331d, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌, objectType=article, longId=194245, objectId=b6fe19424555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6fe19424555, replyNumber=0, likeNumber=77, createdTime=2020-05-17, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6fe19424555, moduleTitle=Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6fe19424555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395032, encodeId=55611395032e5, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, objectType=article, longId=191734, objectId=89b6191e3439, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89b6191e3439, replyNumber=0, likeNumber=65, createdTime=2020-04-10, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89b6191e3439, moduleTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89b6191e3439)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395031, encodeId=80441395031fc, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=33, createdTime=2020-01-08, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395030, encodeId=33e1139503030, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, objectType=article, longId=179625, objectId=df171e962513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df171e962513, replyNumber=0, likeNumber=37, createdTime=2019-09-19, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df171e962513, moduleTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df171e962513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395029, encodeId=29771395029ce, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=JCO：吉西他滨 - 艾日布林组合治疗转移性尿路上皮癌患者：最终报告（NCI-9653）, objectType=article, longId=177452, objectId=7d2e1e7452d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d2e1e7452d0, replyNumber=0, likeNumber=69, createdTime=2019-08-13, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d2e1e7452d0, moduleTitle=JCO：吉西他滨 - 艾日布林组合治疗转移性尿路上皮癌患者：最终报告（NCI-9653）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d2e1e7452d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395028, encodeId=376c139502805, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=瑞普利单抗用于转移性尿路上皮癌，前景值得期待, objectType=article, longId=168238, objectId=7e30168238cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e30168238cd, replyNumber=0, likeNumber=68, createdTime=2019-06-14, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e30168238cd, moduleTitle=瑞普利单抗用于转移性尿路上皮癌，前景值得期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e30168238cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395027, encodeId=a095139502e0f, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Brit J Cancer：转移性尿路上皮癌患者首次化疗失败后，帕博西尼第二阶段临床试验研究, objectType=article, longId=151455, objectId=558a15145559, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=558a15145559, replyNumber=0, likeNumber=64, createdTime=2018-10-22, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=558a15145559, moduleTitle=Brit J Cancer：转移性尿路上皮癌患者首次化疗失败后，帕博西尼第二阶段临床试验研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=558a15145559)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395026, encodeId=97341395026d5, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Sci Rep：肿瘤浸润性淋巴细胞对患有转移性尿路上皮癌且接受铂化疗患者的预后影响, objectType=article, longId=138562, objectId=74ad138562ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74ad138562ae, replyNumber=0, likeNumber=52, createdTime=2018-05-20, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74ad138562ae, moduleTitle=Sci Rep：肿瘤浸润性淋巴细胞对患有转移性尿路上皮癌且接受铂化疗患者的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74ad138562ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395025, encodeId=6ce31395025c7, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期, objectType=article, longId=123956, objectId=a774123956b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a774123956b5, replyNumber=0, likeNumber=72, createdTime=2017-12-21, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a774123956b5, moduleTitle=Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a774123956b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395024, encodeId=9d211395024ef, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。, objectType=article, longId=122363, objectId=cb2d122363b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d122363b2, replyNumber=0, likeNumber=65, createdTime=2017-12-07, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d122363b2, moduleTitle=Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d122363b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395023, encodeId=45f81395023e5, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Eur Urol：转移性尿路上皮癌，先免疫治疗 or 先化疗？, objectType=article, longId=113192, objectId=6cff11319268, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cff11319268, replyNumber=0, likeNumber=75, createdTime=2017-09-20, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cff11319268, moduleTitle=Eur Urol：转移性尿路上皮癌，先免疫治疗 or 先化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cff11319268)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395022, encodeId=e416139502281, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=JAMA Oncol： Durvalumab在局部晚期或转移性尿路上皮癌中疗效如何？, objectType=article, longId=110698, objectId=81a911069830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81a911069830, replyNumber=0, likeNumber=60, createdTime=2017-08-25, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81a911069830, moduleTitle=JAMA Oncol： Durvalumab在局部晚期或转移性尿路上皮癌中疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81a911069830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395021, encodeId=8e791395021e2, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012), objectType=article, longId=87698, objectId=f06c8e69880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f06c8e69880, replyNumber=0, likeNumber=35, createdTime=2017-01-19, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f06c8e69880, moduleTitle=lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f06c8e69880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395020, encodeId=649b1395020c7, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Lancet Oncol：Nivolumab治疗复发转移性尿路上皮癌已初见成效（CheckMate-032）, objectType=article, longId=79710, objectId=edd4e9710ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edd4e9710ea, replyNumber=0, likeNumber=49, createdTime=2016-10-12, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edd4e9710ea, moduleTitle=Lancet Oncol：Nivolumab治疗复发转移性尿路上皮癌已初见成效（CheckMate-032）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edd4e9710ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395019, encodeId=7a4a139501969, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, objectType=article, longId=64211, objectId=be266421184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be266421184, replyNumber=0, likeNumber=60, createdTime=2016-03-08, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be266421184, moduleTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be266421184)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性尿路上皮癌

2020-05-29

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Lancet oncol：卡博替尼治疗铂耐药的转移性尿路上皮癌

2020-07-14

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗

2020-07-03

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌

2020-06-24

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌

2020-05-17

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌

2020-04-10

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-01-08

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查

2019-09-19

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

JCO：吉西他滨 - 艾日布林组合治疗转移性尿路上皮癌患者：最终报告（NCI-9653）

2019-08-13

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

瑞普利单抗用于转移性尿路上皮癌，前景值得期待

2019-06-14

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Brit J Cancer：转移性尿路上皮癌患者首次化疗失败后，帕博西尼第二阶段临床试验研究

2018-10-22

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Sci Rep：肿瘤浸润性淋巴细胞对患有转移性尿路上皮癌且接受铂化疗患者的预后影响

2018-05-20

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Lancet：Atezolizumab不能延长PD-L1过表达的铂难治性转移性尿路上皮癌患者生存期

2017-12-21

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。

2017-12-07

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Eur Urol：转移性尿路上皮癌，先免疫治疗 or 先化疗？

2017-09-20

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

JAMA Oncol： Durvalumab在局部晚期或转移性尿路上皮癌中疗效如何？

2017-08-25

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012)

2017-01-19

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Lancet Oncol：Nivolumab治疗复发转移性尿路上皮癌已初见成效（CheckMate-032）

2016-10-12

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好

2016-03-08

科室
- - 订阅+
  - 更多科室
工具
服务